Unleashing the potential of a low CpG Passer transposon for superior CAR-T cell therapy
Collectively, our results demonstrate the high safety and efficacy of non-viral, low CpG Passer transposon CAR-T cells, offering new avenues for improving CAR-T cell efficacy while minimizing <i>in vivo</i> inflammation.
Authors
- Yan Sun (ORCID: https://orcid.org/0000-0002-6616-8784)
- Yuan Fang (ORCID: https://orcid.org/0000-0003-0483-2237)
- Di Meng
- Tao Liu (ORCID: https://orcid.org/0000-0001-6187-3540)
- Jingbo Cheng
- Qijun Qian (ORCID: https://orcid.org/0000-0002-3285-5009)
- Pingjing Zhang (ORCID: https://orcid.org/0000-0002-6129-4685)
- M. Shao (ORCID: https://orcid.org/0009-0004-9550-9965)
- J Zeng (ORCID: https://orcid.org/0009-0002-5249-6311)
- Pei Wang (ORCID: https://orcid.org/0000-0002-0538-7641)
- Qian Huang
- Xiaodie Wang
Institutions
- Shanghai University (CN)
- Shanghai Cell Therapy Research Institute (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-02-06
- DOI
- https://doi.org/10.3389/fimmu.2025.1541653
- Citations
- 2
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.09